Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit

Movement Disorders

Volumn 26, Issue 4, 2011, Pages 739-742

  Saccà, Francesco ^a   Piro, Raffaele ^a   De Michele, Giuseppe ^a   Acquaviva, Fabio ^a   Antenora, Antonella ^a   Carlomagno, Guido ^a   Cocozza, Sergio ^a   Denaro, Alessandra ^a   Guacci, Anna ^a   Marsili, Angela ^a   Perrotta, Gaetano ^a   Puorro, Giorgia ^a   Cittadini, Antonio ^a   Filla, Alessandro ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Epoetin alfa; Erythropoietin; Frataxin; Friedreich's ataxia; Iron

Indexed keywords

ERYTHROPOIETIN; FERRITIN; FRATAXIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE COUNT; FEMALE; FERRITIN BLOOD LEVEL; FLU LIKE SYNDROME; FRIEDREICH ATAXIA; HEART MUSCLE CONTRACTILITY; HEMATOCRIT; HORMONE BLOOD LEVEL; HOT FLUSH; HUMAN; HYPOTENSION; INJECTION SITE REACTION; IRON BLOOD LEVEL; LIMB DISEASE; LOW DRUG DOSE; MALE; MYALGIA; NAUSEA; NIGHT SWEAT; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; REPEATED DRUG DOSE; SIDE EFFECT; TRANSFERRIN BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; FRIEDREICH ATAXIA; HEMATINICS; HEMATOCRIT; HUMANS; IRON; IRON-BINDING PROTEINS; MALE; TIME FACTORS;

EID: 79955016332     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23435     Document Type: Article

References (19)

1. Harding AE. Friedreich's ataxia: a clinical and genetic study of 90 families with analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981; 104: 589-620.
2. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996; 271: 1423-1427.
3. Pianese L, Turano M, Lo Casale MS, et al. Real time PCR quantification of frataxin mRNA in the peripheral blood leukocytes of Friedreich's ataxia patients and carriers. J Neurol Neurosurg Psychiatry 2004; 75: 1061-1063.
4. Stehling O, Elsasser HP, Bruckel B, et al. Iron-sulfur protein maturation in human cells: evidence for a function of frataxin. Hum Mol Genet 2004; 13: 3007-3015.
5. Cavadini P, O'Neill HA, Benada O, Isaya G. Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich's ataxia. Hum Mol Genet 2002; 11: 217-227.
6. Bulteau AL, O'Neill HA, Kennedy MC, et al. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 2004; 305: 242-245.
7. Masuda S, Nagao M, Takanaka K, et al. Functional erythropoietin receptor of the cells with neuronal characteristics: comparison with receptor properties of erythroid cells. J Biol Chem 1993; 268: 11208-11216.
8. Sanchez PE, Fares RP, Risso JJ, et al. Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. Proc Natl Acad Sci USA 2009; 106: 9848-9853.
9. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95: 4635-4640.
10. Gunnarson E, Song Y, Kowalewski JM, et al. Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection. Proc Natl Acad Sci USA 2009; 106: 1602-1607.
11. Sturm B, Stupphann D, Kaun C, et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Invest 2005; 35: 711-717.
12. Acquaviva F, Castaldo I, Filla A, et al. Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression. Cerebellum 2008; 7: 360-365.
13. Boesch S, Sturm B, Hering S, et al. Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin. Ann Neurol 2007; 62: 521-524.
14. Boesch S, Sturm B, Hering S, et al. Neurological effects of recombinant human erythopoietin in Friedreich's ataxia: a clinical pilot trial. Mov Disord 2008; 23: 1940-1944.
15. Ramakrishnan R, Cheung WK, Wacholtz MC, et al. Pharmacokinetics and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 2004; 44: 991-1002.
16. Willis JH, Isaya G, Gakh O, et al. Lateral-flow immunoassay for the frataxin protein in Friedreich's ataxia patients and carriers. Mol Genet Metab 2008; 94: 491-497.
17. Trouillas P, Takayanagi T, Hallet M, et al. International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. J Neurol Sci 1997; 145: 205-211.
18. Weiss G, Theurl I, Eder S, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 2009; 39: 883-890.
19. Lasocki S, Millot S, Andrieu V, et al. Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia. Crit Care Med 2008; 36: 2388-2394.